Effects of sodium-dependent glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus and asymptomatic heart failure


Here are the Effects of sodium-dependent glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus and asymptomatic heart failure journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.

Effects of sodium dependent glucose, side effects of gabapentin, side effects of ozempic, effects of sodium dependent glucose transporter 2 inhibitors biology, effects of sodium dependent glucose transporter 2 cast, effects of sodium dependent glucose transporter 2 imdb, effects of sodium dependent glucose transporter 4, effects of sodium dependent glucose transporter 2 inhibitors definition, effects of sodium dependent glucose transporter saturation, effects of sodium dependent glucose transporter deficiency.

Effects of sodium-dependent glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus and asymptomatic heart failure

Sodium-dependent glucose transporter 2 inhibitors (SGLT2i) have been increasingly used with proven efficacy in patients with heart failure (HF), regardless of diabetes status. Grubić Rotkvić et al recently published an observational study on SGLT2i therapy in patients with type 2 diabetes mellitus and asymptomatic HF. They found that the use of SGLT2i led to reduced cardiac load and improved cardiovascular performance, reinforcing the evolving paradigm that SGLT2i are not merely glucose-lowering agents but are integral to the broader management of cardiovascular risk in patients with type 2 diabetes mellitus. The study by Grubić Rotkvić et al contributes to the growing body of literature supporting the early use of SGLT2i in patients with diabetic cardiomyopathy, offering a potential strategy to mitigate the progression of HF. Future larger studies should be conducted to confirm these findings, and explore the long-term cardiovascular benefits of SGLT2i, particularly in a symptomatic patients at risk of developing HF. ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Authors : Laimoud M.H.; Raslan I.R.

Source : Baishideng Publishing Group Inc

Article Information

Year 2024
Type Article
DOI 10.4330/wjc.v16.i11.665
ISSN 19498462
Volume 16

You can download the article here


If You have any problem, contact us here


Support Us:

Download Now Buy me a coffee Request Paper Here